QLT (USA)(NASDAQ:QLTI) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Earnings per share were $-0.10. Analysts had estimated an EPS of $-0.11.
QLT (USA) (QLTI) remained unchanged at the close of Wednesday session. Even as the volume increased to 1,55,087 ,the shares failed to make any impression and ended at 0 points or 0.00% at $1.42. The trading session commenced at $1.44 and the stock hit a high of $1.44 and touched $1.38 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $2.731848 and the 52-week low is $1.22. The company has a market cap of $75 M and has approximately 5,28,29,398 outstanding shares.
Several Insider Transactions has been reported to the SEC. On Dec 30, 2015, Jason Aryeh (director) purchased 18,400 shares at $2.49 per share price.Also, On Jun 17, 2015, Capital Master, L.p. Axial (10% owner) sold 7,563,053 shares at $3.47 per share price.
QLT Inc. (QLT) is a biotechnology company engaged in the development and commercialization of ocular products. QLT is engaged in the development of QLT091001 for the treatment of Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP). QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal a biochemical component of the visual retinoid cycle and is used for the treatment of certain age-related and inherited retinal degenerative diseases. The Company’s QLT091001 product candidate has completed a Phase Ib retreatment study for the treatment of LCA and RP a Phase Ib study for the treatment of RP with autosomal dominant mutation in retinal pigment epithelium protein 65 (RPE65) and a Phase IIa study for the treatment of impaired dark adaptation (IDA). QLT091001 has received orphan drug designations for the treatment of LCA and RP by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA).